Tempus Presents 31 Abstracts at AACR Annual Meeting 2026

Research highlights include insights on gene fusions, microsatellite instability, and predictive biomarkers in cancer

Apr. 15, 2026 at 5:03am

Got story updates? Submit your updates here. ›

A highly abstract, geometric painting in soft blues, greens, and grays, featuring sweeping arcs, concentric circles, and precise biological spirals, conceptually representing the complex molecular forces and structures underlying cancer biology.Tempus' multimodal data and AI-powered insights are uncovering new frontiers in precision oncology, transforming how cancer is understood and treated.San Diego Today

Tempus AI, Inc., a leader in AI-powered precision medicine, announced the acceptance of 31 abstracts for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. The research covers a range of topics, including the co-occurrence of gene fusions and microsatellite instability in colorectal cancer, the use of KMT2C mutations as a biomarker for platinum-based therapy response, and the identification of immune subtypes in metastatic non-small cell lung cancer.

Why it matters

Tempus' research at the AACR meeting underscores the company's commitment to advancing the field of oncology through the practical application of AI and multimodal data analysis. The findings have the potential to transform cancer diagnosis and treatment by uncovering clinically relevant insights that deepen the understanding of tumor biology and guide more personalized therapeutic strategies.

The details

Tempus' research highlights include: 1) The co-occurrence of gene fusions and microsatellite instability (MSI) in colorectal cancer, which defines a distinct molecular subtype that may influence therapeutic stratification; 2) The identification of KMT2C mutations as a predictive biomarker for sensitivity to platinum-based chemotherapy, particularly in colorectal and gastrointestinal cancers; 3) The exploration of RNA expression patterns of 47 cell surface proteins in small cell lung cancer; 4) The development of a machine learning model to predict retained retinoblastoma (Rb) function in small cell lung cancer; and 5) The identification of four biologically distinct immune subtypes in metastatic non-small cell lung cancer that may guide subtype-specific treatment strategies.

  • The AACR Annual Meeting 2026 will take place from April 17-22 in San Diego.
  • Tempus will host an Exhibitor Spotlight Theater session on Monday, April 20, 2026, from 10:00-11:00 AM PST.

The players

Tempus AI, Inc.

A technology company leading the adoption of AI to advance precision medicine, with one of the world's largest libraries of multimodal data and an operating system to make that data accessible and useful.

Kate Sasser, PhD

Chief Scientific Officer at Tempus.

Neil Bence, PhD

Senior Vice President of the Protein Homeostasis Thematic Research Center at Bristol Myers Squibb.

Got photos? Submit your photos here. ›

What they’re saying

“The research that Tempus is presenting at this year's AACR annual meeting underscores the scale and real-world impact of Tempus' multimodal dataset and AI-enabled diagnostic solutions.”

— Kate Sasser, Chief Scientific Officer at Tempus

“Across these studies, our researchers are uncovering clinically relevant insights that not only deepen our understanding of tumor biology, but also have the potential to transform how cancer is diagnosed and treated.”

— Kate Sasser, Chief Scientific Officer at Tempus

What’s next

Tempus is currently conducting laboratory studies to further clarify the mechanisms behind the findings, particularly the role of KMT2C mutations as a predictive biomarker for platinum-based therapy response.

The takeaway

Tempus' research presented at the AACR Annual Meeting 2026 demonstrates the company's commitment to leveraging AI and multimodal data analysis to advance precision medicine and improve outcomes for cancer patients. The insights gained from these studies have the potential to redefine our understanding of tumor biology and guide more personalized treatment strategies.